HomeProductsBioactive CompoundsDNA Damage & RepairATM/ATRBerzosertib
Chemical structure of CAS 1232416-25-9

Berzosertib

CAS No.1232416-25-9
MDL No.MFCD27976794
MFC24H25N5O3S
MW463.60
InChI KeyJZCWLJDSIRUGIN-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

3-[3-(4-(methylaminomethyl)phenyl)-5-isoxazolyl]-5-(4-propan-2-ylsulfonylphenyl)-2-pyrazinamine, a sulfonamide.

CAS No.1232416-25-9
Product NameBerzosertib

Biological Targets

ATR

Associated Conditions

oral squamous cell carcinoma·ovarian cancer·head and neck carcinoma·non-small cell lung carcinoma·laryngeal squamous cell carcinoma·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Oncoprotein SET dynamically regulates cellular stress response through nucleocytoplasmic transport in breast cancer.

Cell biology and toxicology • Vol. 39, Issue 4 • 2023
PMID: 36534342DOI: 10.1007/s10565-022-09784-4

Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy.

Pharmacology & therapeutics • Vol. 210 • 2020
PMID: 32109490DOI: 10.1016/j.pharmthera.2020.107518

Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies.

Therapeutic advances in medical oncology • Vol. 10 • 2018
PMID: 30023007PMC: PMC6047242DOI: 10.1177/1758835918786658

The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma.

Cancer letters • Vol. 432 • 2018
PMID: 29890208DOI: 10.1016/j.canlet.2018.06.010

Documentation